Cargando…

A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis

OBJECTIVE: To assess the clinical outcomes of patients prescribed the World Health Organization (WHO) Category II retreatment regimen for tuberculosis (TB). DESIGN: A systematic review of the literature was performed by searching Medscape, Embase and Scopus databases for cohort studies and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, D. B., Meghji, J., Squire, S. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149242/
https://www.ncbi.nlm.nih.gov/pubmed/30236179
http://dx.doi.org/10.5588/ijtld.17.0705
_version_ 1783356831181045760
author Cohen, D. B.
Meghji, J.
Squire, S. B.
author_facet Cohen, D. B.
Meghji, J.
Squire, S. B.
author_sort Cohen, D. B.
collection PubMed
description OBJECTIVE: To assess the clinical outcomes of patients prescribed the World Health Organization (WHO) Category II retreatment regimen for tuberculosis (TB). DESIGN: A systematic review of the literature was performed by searching Medscape, Embase and Scopus databases for cohort studies and clinical trials reporting outcomes in adult patients on the Category II retreatment regimen. RESULTS: The proportion of patients successfully completing the retreatment regimen varied from 27% to 92% in the 39 studies included in this review. In only 2/39 (5%) studies was the treatment success rate > 85%. There are very few data concerning outcomes in patients categorised as ‘other’, and outcomes in this subgroup are variable. Of the five studies reporting disaggregated outcomes in human immunodeficiency virus (HIV) positive people, four demonstrated worse outcomes than in HIV-negative people on the retreatment regimen. Only four studies reported disaggregated outcomes in patients with isoniazid (INH) resistance, and treatment success rates varied from 11% to 78%. CONCLUSION: Clinical outcomes on the Category II retreatment regimen are poor across various populations. Improvements in management should consider the holistic treatment of comorbidity and comprehensive approaches to drug resistance in patients with recurrent TB, including a standardised approach for the management of INH resistance in patients who develop recurrent TB in settings without reliable access to comprehensive drug susceptibility testing.
format Online
Article
Text
id pubmed-6149242
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher International Union Against Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-61492422018-10-01 A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis Cohen, D. B. Meghji, J. Squire, S. B. Int J Tuberc Lung Dis Original Articles OBJECTIVE: To assess the clinical outcomes of patients prescribed the World Health Organization (WHO) Category II retreatment regimen for tuberculosis (TB). DESIGN: A systematic review of the literature was performed by searching Medscape, Embase and Scopus databases for cohort studies and clinical trials reporting outcomes in adult patients on the Category II retreatment regimen. RESULTS: The proportion of patients successfully completing the retreatment regimen varied from 27% to 92% in the 39 studies included in this review. In only 2/39 (5%) studies was the treatment success rate > 85%. There are very few data concerning outcomes in patients categorised as ‘other’, and outcomes in this subgroup are variable. Of the five studies reporting disaggregated outcomes in human immunodeficiency virus (HIV) positive people, four demonstrated worse outcomes than in HIV-negative people on the retreatment regimen. Only four studies reported disaggregated outcomes in patients with isoniazid (INH) resistance, and treatment success rates varied from 11% to 78%. CONCLUSION: Clinical outcomes on the Category II retreatment regimen are poor across various populations. Improvements in management should consider the holistic treatment of comorbidity and comprehensive approaches to drug resistance in patients with recurrent TB, including a standardised approach for the management of INH resistance in patients who develop recurrent TB in settings without reliable access to comprehensive drug susceptibility testing. International Union Against Tuberculosis and Lung Disease 2018-10 2018-10-01 /pmc/articles/PMC6149242/ /pubmed/30236179 http://dx.doi.org/10.5588/ijtld.17.0705 Text en © 2018 Cohen et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Articles
Cohen, D. B.
Meghji, J.
Squire, S. B.
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title_full A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title_fullStr A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title_full_unstemmed A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title_short A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
title_sort systematic review of clinical outcomes on the who category ii retreatment regimen for tuberculosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149242/
https://www.ncbi.nlm.nih.gov/pubmed/30236179
http://dx.doi.org/10.5588/ijtld.17.0705
work_keys_str_mv AT cohendb asystematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis
AT meghjij asystematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis
AT squiresb asystematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis
AT cohendb systematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis
AT meghjij systematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis
AT squiresb systematicreviewofclinicaloutcomesonthewhocategoryiiretreatmentregimenfortuberculosis